Publications by authors named "M F Roudaut"
Article Synopsis
- - The liver is crucial for managing lipoproteins, and creating effective lipid-lowering therapies requires advanced in vitro models that mimic liver functions better than current hepatocyte-like cells (HLCs).
- - Researchers aimed to enhance HLC maturation by using a 3D model with Biomimesys®, which allows human-induced pluripotent stem cells (hiPSCs) to form functional liver organoids.
- - After a 28-day maturation, the liver organoids showed improved gene expression, better cell organization, and significant functional abilities, such as lipid accumulation and production of essential proteins, offering a valuable tool for studying lipoprotein metabolism.
Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver's Extracellular Matrix.
Bioengineering (Basel)
September 2022
The 3Rs guidelines recommend replacing animal testing with alternative models. One of the solutions proposed is organ-on-chip technology in which liver-on-chip is one of the most promising alternatives for drug screening and toxicological assays. The main challenge is to achieve the relevant in vivo-like functionalities of the liver tissue in an optimized cellular microenvironment.
View Article and Find Full Text PDFProprotein convertase subtilisin kexin type 9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) cholesterol metabolism and the target of lipid-lowering drugs. PCSK9 is mainly expressed in hepatocytes. Here, we show that PCSK9 is highly expressed in undifferentiated human induced pluripotent stem cells (hiPSCs).
View Article and Find Full Text PDFBackground: Type 2 diabetes mellitus (T2DM) is a chronic, progressive condition where the primary treatment goal is to maintain control of glycated haemoglobin (HbA1c). In order for healthcare decision makers to ensure patients receive the highest standard of care within the available budget, the clinical benefits of each treatment option must be balanced against the economic consequences. The aim of this study was to assess the cost-effectiveness of dapagliflozin, the first-in-class sodium-glucose co-transporter 2 (SGLT2) inhibitor, compared with a dipeptidyl peptidase-4 inhibitor (DPP-4i), when added to metformin for the treatment of patients with T2DM inadequately controlled on metformin alone.
View Article and Find Full Text PDFObjective: To identify and compare health-economic models that were developed to evaluate the cost-effectiveness of treatments for type 2 diabetes mellitus (T2DM), and their use within Health Technology Assessments (HTAs).
Methods: In total, six commonly used databases were searched for articles published between October 2008 and January 2013, using a protocolized search strategy and inclusion criteria. The websites of HTA organizations in nine countries, and proceedings from five relevant conferences, were also reviewed.